- Annovis Announces New Publication in a Peer-Reviewed Journal
- Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
- Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
- Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
- Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
- Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
- Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
- Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
- Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
- Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
More ▼
Key statistics
On Tuesday, Annovis Bio Inc (ANVS:NYQ) closed at 6.65, 38.83% above the 52 week low of 4.79 set on May 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.40 |
---|---|
High | 7.40 |
Low | 6.43 |
Bid | 6.67 |
Offer | 7.94 |
Previous close | 6.65 |
Average volume | 442.49k |
---|---|
Shares outstanding | 11.17m |
Free float | 8.36m |
P/E (TTM) | -- |
Market cap | 74.29m USD |
EPS (TTM) | -5.04 USD |
Data delayed at least 15 minutes, as of May 29 2024 00:00 BST.
More ▼